Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet
Alcon (SIX/NYSE: ALC) has launched SYSTANE PRO Preservative-Free (PF) in the U.S., its latest over-the-counter eye drop for dry eye relief. The product features a unique triple action, preservative-free formula that includes hyaluronate, nano-sized lipids, and HP-Guar, making it the longest-lasting eye drop in the SYSTANE portfolio.
The launch addresses a significant market need, as dry eye disease affects approximately 45.5 million people in the United States and 1.5 billion globally. SYSTANE PRO PF works by providing sustained hydration, restoring tear film stability, and protecting against further eye irritation. The product will be available in the U.S. starting this month, with expansion to additional markets planned for 2026.
SYSTANE is currently the #1 global consumer brand of artificial tears, and this new addition strengthens Alcon's position in the dry eye treatment market.
Alcon (SIX/NYSE: ALC) ha lanciato SYSTANE PRO senza conservanti (PF) negli Stati Uniti, il suo ultimo collirio da banco per il sollievo dalla secchezza oculare. Il prodotto presenta una formula unica a tripla azione, priva di conservanti, che include ialuronato, lipidi di dimensioni nanometriche e HP-Guar, rendendolo il collirio più duraturo nel portafoglio SYSTANE.
Il lancio risponde a un'importante necessità di mercato, poiché la malattia dell'occhio secco colpisce circa 45,5 milioni di persone negli Stati Uniti e 1,5 miliardi a livello globale. SYSTANE PRO PF agisce fornendo idratazione prolungata, ripristinando la stabilità del film lacrimale e proteggendo contro ulteriori irritazioni oculari. Il prodotto sarà disponibile negli Stati Uniti a partire da questo mese, con un'espansione in ulteriori mercati prevista per il 2026.
SYSTANE è attualmente il marchio di lacrime artificiali numero 1 a livello globale e questa nuova aggiunta rafforza la posizione di Alcon nel mercato del trattamento dell'occhio secco.
Alcon (SIX/NYSE: ALC) ha lanzado SYSTANE PRO sin conservantes (PF) en EE. UU., su último colirio de venta libre para el alivio de los ojos secos. El producto presenta una fórmula única de triple acción, libre de conservantes, que incluye hialuronato, lípidos de tamaño nanométrico y HP-Guar, convirtiéndolo en el colirio de mayor duración en la cartera de SYSTANE.
El lanzamiento aborda una necesidad significativa del mercado, ya que la enfermedad del ojo seco afecta a aproximadamente 45,5 millones de personas en los Estados Unidos y 1,5 mil millones a nivel mundial. SYSTANE PRO PF funciona proporcionando hidratación sostenida, restaurando la estabilidad de la película lagrimal y protegiendo contra más irritación ocular. El producto estará disponible en EE. UU. a partir de este mes, con planes de expansión a otros mercados para 2026.
SYSTANE es actualmente la marca de lágrimas artificiales número 1 a nivel mundial, y esta nueva adición refuerza la posición de Alcon en el mercado del tratamiento de ojos secos.
알콘 (SIX/NYSE: ALC)은 미국에서 SYSTANE PRO 방부제 없는 (PF)를 출시했습니다. 이는 건조한 눈을 위한 최신 일반의약품 점안액입니다. 이 제품은 히알루론산, 나노 크기의 지질, HP-Guar를 포함한 독특한 삼중 작용의 방부제 없는 포뮬러를 특징으로 하며, SYSTANE 포트폴리오에서 가장 오랫동안 지속되는 점안액입니다.
이번 출시는 시장의 중요한 필요를 충족시키며, 건조한 눈 질환은 미국에서 약 4,550만 명, 전 세계적으로 15억 명에게 영향을 미칩니다. SYSTANE PRO PF는 지속적인 수분 공급, 눈물막 안정성 회복, 추가적인 눈 자극 방지를 통해 작용합니다. 이 제품은 이번 달부터 미국에서 판매될 예정이며, 2026년에는 추가 시장으로의 확장이 계획되어 있습니다.
SYSTANE은 현재 세계에서 가장 큰 인공 눈물 소비 브랜드이며, 이번 새로운 추가는 알콘의 건조한 눈 치료 시장에서의 입지를 강화합니다.
Alcon (SIX/NYSE: ALC) a lancé SYSTANE PRO sans conservateurs (PF) aux États-Unis, son dernier collyre en vente libre pour le soulagement des yeux secs. Le produit présente une formule unique à triple action, sans conservateurs, qui comprend de l'hyaluronate, des lipides de taille nanométrique et de l'HP-Guar, ce qui en fait le collyre le plus durable du portefeuille SYSTANE.
Ce lancement répond à un besoin important du marché, car la maladie de l'œil sec touche environ 45,5 millions de personnes aux États-Unis et 1,5 milliard dans le monde. SYSTANE PRO PF agit en fournissant une hydratation durable, en restaurant la stabilité du film lacrymal et en protégeant contre d'autres irritations oculaires. Le produit sera disponible aux États-Unis à partir de ce mois-ci, avec une expansion vers d'autres marchés prévue pour 2026.
SYSTANE est actuellement la marque de larmes artificielles numéro 1 dans le monde, et cette nouvelle addition renforce la position d'Alcon sur le marché du traitement des yeux secs.
Alcon (SIX/NYSE: ALC) hat SYSTANE PRO ohne Konservierungsstoffe (PF) in den USA eingeführt, sein neuestes rezeptfreies Augentropfenprodukt zur Linderung von trockenen Augen. Das Produkt bietet eine einzigartige, konservierungsmittelfreie Formel mit dreifacher Wirkung, die Hyaluronat, nano-große Lipide und HP-Guar enthält, wodurch es die am längsten haltbaren Augentropfen im SYSTANE-Portfolio sind.
Die Markteinführung erfüllt einen erheblichen Marktbedarf, da etwa 45,5 Millionen Menschen in den Vereinigten Staaten und 1,5 Milliarden weltweit von trockenen Augen betroffen sind. SYSTANE PRO PF wirkt, indem es eine anhaltende Hydratation bietet, die Stabilität des Tränenfilms wiederherstellt und vor weiteren Augenreizungen schützt. Das Produkt wird ab diesem Monat in den USA erhältlich sein, mit einer geplanten Expansion in weitere Märkte im Jahr 2026.
SYSTANE ist derzeit die weltweit führende Marke für künstliche Tränen, und diese neue Ergänzung stärkt die Position von Alcon im Markt für die Behandlung trockener Augen.
- Launch of new product expanding company's leading dry eye portfolio
- Addresses large market opportunity (45.5M US patients, 1.5B globally)
- Product features innovative triple-action formula
- Maintains #1 global market position in artificial tears
- None.
Insights
The launch of SYSTANE PRO Preservative-Free marks a significant advancement in Alcon's $44.3B eye care business, particularly in the lucrative over-the-counter segment. The product's innovative triple-action formula addresses a critical market need, targeting the substantial 45.5 million US patients and 1.5 billion global patients affected by dry eye disease.
The preservative-free aspect is particularly noteworthy as it aligns with growing consumer preference for gentler formulations, especially among chronic dry eye sufferers and post-surgical patients. This positions SYSTANE PRO PF in a premium segment of the artificial tears market, where Alcon already holds the #1 global position.
The phased launch strategy - beginning in the US with international expansion planned for 2026 - suggests a carefully orchestrated approach to market penetration. This allows Alcon to establish strong market presence domestically before leveraging their global distribution network. The timing of the international rollout in 2026 could contribute meaningfully to revenue growth in the vision care segment, which represents a substantial portion of Alcon's business.
The product's unique formulation with hyaluronate, nano-sized lipids, and HP-Guar creates significant barriers to entry for competitors, reinforcing Alcon's market leadership. This technological differentiation, combined with the company's established brand equity in the SYSTANE portfolio, positions them to capture a larger share of the growing dry eye market, particularly as digital device usage continues to drive increased demand for eye care solutions.
- SYSTANE PRO Preservative-Free (PF) is the longest lasting dry eye drop in the SYSTANE portfolio1
- SYSTANE PRO PF is a one-of-a-kind multi-dose preservative-free triple action formula that hydrates, restores and protects all types of dry eyes1
- SYSTANE PRO PF will be showcased at SECO 2025 as the latest addition to the SYSTANE line of products, the #1 global consumer brand of artificial tears2
Dry eye disease is one of the most common ocular surface disorders, affecting an estimated 45.5 million people in
“We are proud to introduce SYSTANE PRO PF, the first and only multi-dose preservative-free triple action formula with hyaluronate, nano-sized lipids and HP-Guar that support the active ingredient giving patients long-lasting relief from the symptoms of dry eye,” said Terry Kim, MD, Chief Medical Officer and Head of Global Medical Safety, Alcon. “This is another example of how Alcon is bringing innovation to the SYSTANE portfolio to address the needs of dry eye patients.”
Patients with dry eyes often experience symptoms when moisture retention and tear stability are impacted by a variety of factors including aging, environment and digital device use.4 The unique formulation of SYSTANE PRO PF works to deliver long-lasting dry eye symptom relief for all types of dry eyes.1
“As an Eye Care Professional and global dry eye expert, I know that patients should benefit from the design of a triple action preservative-free formula that includes hyaluronate to address all types of dry eye,” said Dr. Selina McGee, Founder and Chief Optometrist of Bespoke Vision in
The launch begins in the
To learn more about SYSTANE PRO PF, please visit Systane.com.
Important Information for the SYSTANE Family of Products
SYSTANE lubricant eye drops have been clinically proven to reduce the symptoms of dry eye, providing fast, long-lasting relief and comfort. SYSTANE is the #1 global consumer brand of artificial tears.2 SYSTANE COMPLETE provides symptom relief for people who suffer from evaporative dry eye, aqueous tear-deficient dry eye or mixed dry eye. SYSTANE ULTRA is designed for dry eye with aqueous deficient patients. SYSTANE BALANCE lubricant eye drops are designed specifically for patients with evaporative dry eye associated with meibomian gland dysfunction. SYSTANE HYDRATION gives long-lasting relief of dry eye symptoms for moderate or chronic sufferers or patients who are recovering from corneal or other eye surgery.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
References
- Alcon Data on File, 2025.
- IQVIA Consumer Health Customized Insights.
- Dry Eye Products Markets Report, Market Scope, 2023.
-
Market Scope LLC. 2020 Dry Eye Products Report: A Global Market Analysis for 2019 to 2025.
St. Louis, MO.
Connect with us on
View source version on businesswire.com: https://www.businesswire.com/news/home/20250222227163/en/
Investor Relations
Daniel Cravens, Allen Trang
+ 41 589 112 110 (
+ 1 817 615 2789 (
investor.relations@alcon.com
Media Relations
Steven Smith
+ 41 589 112 111 (
+ 1 817 551 8057 (
globalmedia.relations@alcon.com
Source: Alcon Inc. Investors
FAQ
When will SYSTANE PRO Preservative-Free (ALC) be available in the US market?
What are the key features of Alcon's new SYSTANE PRO Preservative-Free eye drops?
How many people could benefit from Alcon's new dry eye treatment?
When will SYSTANE PRO PF expand to international markets beyond the US?
What is the market position of SYSTANE in the artificial tears segment?
